Risk-benefit Modelling informs the increasing focus on the safety and efficacy of new therapies from a population perspective

It jointly evaluates the risks and benefits of competing therapies. This analysis allows the explicit incorporation of patient or societal preferences for the targeted health states, and is a flexible strategy that can employ trial or real-world safety and efficacy/effectiveness data. A risk-benefit Modelling approach is particularly valuable for therapies with potentially contentious or poorly understood safety profiles.

To jointly assess the risks and benefits of treatments for a given condition, we typically employ a Modelling approach.

Model inputs may be synthesised using a variety of methods:

  • Systematic literature review
  • Meta-analysis
  • Administrative database analysis
  • Chart reviews
  • Prospective data collection and registries 

Regulators have taken a special interest in risk benefit studies because of their contribution towards the lifecycle management approach to drug licensure that many countries are moving towards.

Our epidemiology team has a wealth of experience in conducting risk-benefit Modelling and we are able to use this expertise to provide a well informed and thorough service either as a standalone product or in conjunction with our other services.